Close Menu

NEW YORK (GenomeWeb) — Wells Fargo has downgraded Cepheid to Market Perform from Outperform, calling into question the company's "credibility and visibility" after it revised its 2017 profit outlook.

Cepheid reaffirmed its 2015 fourth quarter outlook at the Piper Jaffray Healthcare Conference on Tuesday, and also provided initial revenue guidance of $618 million to $635 million for Fiscal Year 2016. The company also updated its FY 2017 outlook to a gross margin of 56 percent to 58 percent, compared to its previous guidance of 60 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.